U.S. pharma giant copyright scrapped two experimental weight loss supplements final calendar year—a after-day by day pill, lotiglipron, due to elevated liver enzymes plus a two times-day by day pill, danuglipron, on account of strong Unwanted effects—but CEO Albert Bourla has said th